BOCI launches CLNs for retail investors in Hong Kong

Called Flexibond, the five-year credit-linked notes are referenced to PCCW-HKT (HKT), a subsidiary of Hong Kong-based integrated communications company PCCW. Rated BBB by Standard and Poor’s (S&P) and Baa2 by Moody’s Investor Services, the notes offer investors the option of either redeeming the investments at 109% on maturity, or to exchange the investment for HSBC shares based on a conversion price on or before maturity – set at 120% of HSBC’s average closing price for the first three trading days after the issue. In the case of a credit default, the bonds will be redeemed and investors will be repaid with the July 2013 PCCW HKTC Capital bond.

“Flexibond is the first investment product BOCI has launched in the Hong Kong retail market,” said Polly Wong, vice-president of equity derivatives at the bank in Hong Kong. “In the future BOCI will develop more structured investment products to facilitate the market development and satisfy the needs of investors.” These could include more credit-linked products and equity-linked products - in the form of bonds or principal-protected structures - and possibly listed warrants.

“In view of the current ever-changing market environment, the design of this new product is to offer investors another choice of quality investment with lower risk exposure,” added Wong. “Not only does Flexibond help satisfy investor need for safer investments and higher returns, but it also brings in additional opportunities for capital enhancement. When the equity market performs well, investors who choose to switch to HSBC shares may enjoy an investment return of more than 9%.”

The notes are being issued by the bank’s structured investment product platform, boci.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here